Glycan Conjugates for Robust IgG Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current carbohydrate-based cancer vaccines, such as those targeting Globo H, face challenges in eliciting a robust IgG immune response, which is crucial for long-term memory and effective cancer therapy, with many vaccines inducing higher levels of IgM antibodies but failing to induce strong IgG responses.
Innovation Solution
Modification of Globo H at the reducing end glucose or non-reducing end fucose with specific groups, such as fluoro, azido, or phenyl groups, to create synthetic glycan conjugates that, when combined with a carrier protein like diphtheria toxoid CRM197 and an adjuvant like glycolipid C34, elicit a robust IgG antibody response capable of recognizing and mediating cytotoxicity against tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional carbohydrate-based vaccines (e.g., Theratope, GMK) are used with carrier proteins and adjuvants, then IgM antibody response is induced, but robust IgG antibody response and long-term immune memory are not achieved
Solution Approach 1:
The patent modifies the chemical structure of Globo H by introducing unnatural glycosidic linkages (β2,6-linked mannose instead of natural α1,3-linkage) and N-acetylglucosamine substitutions at specific positions (C4 of Galactose II, C6 of Fucose). These structural parameter changes transform the antigen from poorly immunogenic natural form to highly immunogenic modified form that elicits robust IgG response with long-term memory, resolving the contradiction between response quality and response level.
Solution Approach 2:
The patent creates a composite vaccine formulation combining modified Globo H antigen with carrier protein (CRM197 or KLH) and adjuvant (QS-21 or glycolipid C34). This composite structure leverages the immunogenic properties of each component: the modified glycan provides T-independent B-cell activation, the carrier protein provides T-cell epitopes for class switching, and the adjuvant enhances overall immune response. This composite approach achieves both high IgG levels and long-term memory.
2Reliability
If natural Globo H structure is used, then the vaccine is simple to synthesize, but immunogenicity is poor and cannot elicit strong immune response
Solution Approach 1:
The patent systematically modifies multiple parameters of the Globo H structure: (1) changes glycosidic linkage type (α1,3 to β2,6), (2) changes monosaccharide composition (adding N-acetylglucosamine), (3) modifies substitution positions (C4 of Galactose II, C6 of Fucose). These parameter changes dramatically improve immunogenicity while maintaining a defined synthetic pathway that can be scaled for manufacturing.
Solution Approach 2:
The patent employs a stepwise synthetic approach where the complex modified Globo H is constructed from simpler sugar building blocks (galactose, fucose, mannose, N-acetylglucosamine) through sequential glycosylation reactions. This segmentation of the synthesis process into manageable stages improves ease of manufacture despite the structural complexity, as each stage can be optimized independently.
3Reliability
If conventional vaccine formulations are used, then clinical trials can be conducted, but statistically significant improvement in overall survival rate and time-to-disease is not achieved
Solution Approach 1:
The patent modifies the antigen structure to create unnatural glycan configurations that are not present in natural Globo H, specifically β2,6-linked mannose and N-acetylglucosamine substitutions. These parameter changes produce a vaccine that elicits stronger, more sustained IgG responses with memory formation, translating to improved clinical efficacy metrics such as overall survival rate and time-to-disease in cancer patients.
Solution Approach 2:
The patent uses carrier proteins (CRM197, KLH) as intermediaries that bridge the gap between the modified glycan antigen and the immune system's T-cell dependent response pathway. The carrier protein provides T-cell epitopes that enable class switching from IgM to IgG and generate immunological memory, while the modified glycan structure ensures strong B-cell activation. This intermediary mechanism transforms the vaccine from merely inducing antibodies to generating protective immune memory.
Data Source
Figure 1A~1C
Figure 2~3
AI summary
This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.